Navigation Links
QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
Date:3/30/2008

VANCOUVER, March 31 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today the initiation of patient recruitment into its "CORE" study, a phase II trial being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. ("QPD"), to evaluate the preliminary efficacy and safety of its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension. The punctal plug delivery system is a non-invasive drug delivery system that is being developed with a goal of being capable of delivering a variety of drugs to the eye over time through sustained release to the tear film.

"I believe that a punctal plug drug delivery system could be a catalyst for a paradigm shift in how glaucoma is treated and this clinical study is a critical first step in evaluating a component of this system, and it's potential to help patients manage their disease. If successful, these plugs could eliminate the patient's dosing dependency and possibly provide consistent 24-hour control for intraocular pressure (IOP). Our goal in 2008 is to deliver drug in a punctal plug delivery system to glaucoma patients for periods of approximately 90 days, with the aim of leading to a therapeutic drop in IOP," said Bob Butchofsky, President and Chief Executive Officer of QLT.

This study is a phase II, randomized, masked, parallel-group study of safety and preliminary efficacy of a punctal plug drug delivery system involving up to 60 patients with primary open-angle glaucoma or ocular hypertension. The punctal plug drug delivery system in this study consists of three different concentrations of latanoprost, a prostaglandin analogue.

Prostaglandins represent the largest segment of the U.S. glaucoma market, accounting for approximately $700 million in sales in 2005. Latanoprost is an active ingredient that has been approved by the Food and Drug Administration for reducing elevated intraocular pressure in patients with open-angle glau
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...taract surgery is higher in patients who have take...rged prostate.// According to the 3 medical assoc...e American Society of Cataract and Refractive Surg...tion, mentioning the use of drugs like Flomax (tam...
...a seriously ill toddler his vital heart monitor du... child who suffers from a rare heart condition has...ous attitude. Stephen Leckey has also appealed to ...ess crime to return the monitor that is an vital p...
...sotretinoin has been found to have more dangerous ... even though it is an effective medication for the...as Accutane in the US and as Roaccutane in UK, and...own to clear up severe acne and prevent scarring, ...
...ng in Australia has found that many South Australi...ving regular screenings// through pap smears. The ...ring 2001-04 more than the 66 in 1997-2000. In th...e was highest with 15 deaths during the period. Pr...
Other Medicine News:Health News:Alpha-blockers call for modification in cataract surgery 2Health News:Alpha-blockers call for modification in cataract surgery 3Health News:Callous Thieves Rob An Seriously Ill Child Of His Vital Heart Machine 2Health News:Acne Drug Found To Cause More Harm than Good 2
(Date:10/7/2008)...al abstracts highlighting CIMZIA,s long-term benef...e patients presented at American College,of Gastro...e-FirstCall/ -- Data from two studies,presented th...terology,(ACG) Annual Meeting demonstrate that CIM...nti-TNF alpha (Tumor Necrosis Factor alpha) - prov...
(Date:10/7/2008)...d 15 Patient Cohort Enrolled in Stage A of Trial A...With Carboplatin and Paclitaxel -, TUSTIN, Calif....aceuticals, Inc. (Nasdaq: PPHM ), a clinical stag...antibodies for the treatment of cancer and,hepatit...t has completed,enrollment in the first stage of a...
(Date:10/6/2008)... and CHIPPENHAM, England, October 7 /PRNewswire-Fi...Mothers Index: 4565) and Vectura,Group plc ("Vectu...tudies,evaluating the efficacy, safety and tolerab...f the European Respiratory Society (ERS) in Berlin...ronium bromide), a novel,inhaled long-acting musca...
(Date:10/6/2008)...N, Oct. 6 /PRNewswire-USNewswire/ -- "A return to ...e development is without scientific,justification,...al,Alternatives to Laboratory Animals (ATLA). "An ...ine Research" concludes that vaccine responses in,...ans, and that claims of,chimpanzees, critical role...
Breaking Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Some Immature Brain Cells May Promote Tumors 9157 1Some Immature Brain Cells May Promote Tumors 9157 2Start Your Day the Sun Shower 28TM 29 Way 9152 1Start Your Day the Sun Shower 28TM 29 Way 9152 2Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference 9147 1Kiwa Fertilizers Pass Independent Tests 2483 1Kiwa Fertilizers Pass Independent Tests 2483 2Kiwa Fertilizers Pass Independent Tests 2483 3
... MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gem...preclinical data,from a study of its lead compound...tic leukemia (ALL). The study was discussed in an,...rican Association,for Cancer Research (AACR). Acco...ingle agent activity against ALL blast cells,and ...
...lif. and LOS ANGELES, April 18, 2007,/PRNewswire-F...ata,from two preclinical studies, one identifying ...tylase (HDAC) inhibitor and,another demonstrating ...tyrosine kinase (BTK) inhibitor compounds. The dat...ancer Research (AACR),2007 Annual Meeting being he...
Other Medicine Technology:Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5
... of deflectable curve catheters designed to specif...r patients with small anatomies. Each catheter is ... the finest materials. A unique multi-step process...ion technologies results in the excellent torque a...
... of fixed curve catheters designed to specifically...ents with small anatomies. Each catheter is handcr...inest materials. A unique multi-step process that ...chnologies results in the excellent torque and fle...
4Fr, 5Fr & 6Fr diagnostic electrophysiology catheters with fixed curves.
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism.
Medicine Products: